...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hypertension: An Official Journal of the American Heart Association >Prevalence of Apparent Treatment-Resistant Hypertension in the United States: Comparison of the 2008 and 2018 American Heart Association Scientific Statements on Resistant Hypertension
【24h】

Prevalence of Apparent Treatment-Resistant Hypertension in the United States: Comparison of the 2008 and 2018 American Heart Association Scientific Statements on Resistant Hypertension

机译：美国明显治疗的高血压患病率：2008年和2018年美国心脏协会对抗性高血压的科学陈述的比较

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In 2018, the American Heart Association published a Scientific Statement on resistant hypertension. We compared the prevalence of apparent treatment-resistant hypertension (aTRH) among US adults as defined in the 2018 and 2008 American Heart Association Scientific Statements using data from 4158 participants with hypertension, taking antihypertensive medication in the 2009 to 2014 National Health and Nutrition Examination Survey. Blood pressure (BP) was measured 3 times, and antihypertensive medication classes were identified through a pill bottle review. In both Scientific Statements, aTRH was defined as uncontrolled BP while taking 3 classes of antihypertensive medication or taking 4 classes of antihypertensive medication regardless of BP level. Uncontrolled BP was defined as systolic/diastolic BP 140/90 mmHg (130/80 mmHg for those with diabetes mellitus or chronic kidney disease) in the 2008 Scientific Statement and systolic/diastolic BP 130/80 mmHg (systolic BP 130 mmHg only for low-risk adults 65 years of age) in the 2018 Scientific Statement. The prevalence of aTRH was 17.7% and 19.7% according to the 2008 and 2018 Scientific Statement definitions, respectively (=2.0%; 95% CI, 1.5%-2.7%). Overall, 10.3 million US adults had aTRH according to the 2018 Scientific Statement. The most common 3-drug combination taken included an angiotensin-converting enzyme inhibitor, -blocker, and thiazide diuretic. Using the 2018 definition, 3.2% of US adults with aTRH were taking a thiazide-like diuretic (chlorthalidone or indapamide), and 9.0% were taking a mineralocorticoid receptor blocker (spironolactone or eplerenone). In conclusion, the prevalence of aTRH is only modestly higher using the definition in the 2018 versus 2008 resistant hypertension Scientific Statement.
机译：2018年，美国心脏协会发表了一种关于抗性高血压的科学陈述。比较了2018年和2008年美国心脏协会科学陈述中所定义的美国成年人的表观治疗抗性高血压（ATRH）的患病率，使用来自4158名参与者的高血压的数据，在2009年至2014年全国卫生和营养考试调查中服用抗高血压药物。测量血压（BP）3次，通过药瓶审查鉴定抗高血压药物课程。在科学陈述中，ATRH被定义为不受控制的BP，同时服用3类抗高血压药物或服用4级抗高血压药物，无论BP水平如何。在2008年科学陈述和收缩/舒张型BP 130/80mmHg（仅用于低温的Systolic BP 130mmHg）中，不受控制的BP定义为收缩/舒张型BP 140/90 mmHg（130/80 mmHg或糖尿病或慢性肾脏疾病）的130/80mmHg） - 65岁的成年人）在2018年的科学陈述。根据2008年和2018年科学声明定义，ATRH的患病率分别为17.7％和19.7％（= 2.0％; 95％CI，1.5％-2.7％）。总体而言，根据2018年科学陈述，总共1030万美国成年人有ATRH。所采用的最常见的3-药物组合包括血管紧张素转换酶抑制剂， - Blocker和噻嗪基利尿剂。使用2018年的定义，3.2％的美国成年人采用噻嗪类利尿（Chlorthaldone或吲达咪酰胺），9.0％正在服用矿物质激素受体阻滞剂（螺旋酮或ePlerenone）。总之，使用2018年与2008年抗性高血压科学陈述的定义，ATRH的患病率仅适度更高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号